Reserpine Tablets, USP
Reserpine, USP is an antihypertensive, available as 0.1 mg and 0.25 mg tablets for oral administration.
Reserpine is indicated for the following:
Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.
Published Studies Related to Reserpine
A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. [2005.03]
AIMS: To conduct a preliminary evaluation of the safety and efficacy of reserpine, gabapentin or lamotrigine versus an unmatched placebo control as a treatment for cocaine dependence... CONCLUSIONS: The present findings suggest that reserpine may be worthy of further study as a cocaine dependence treatment.
A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension. [1997.12]
OBJECTIVE: To compare the effectiveness of the combination of hydrochlorothiazide (HCT) plus sustained-release nifedipine with the combination of HCT plus reserpine in lowering high blood pressure (BP) unresponsive to HCT monotherapy... However, further trials should compare BP lowering effects as well as end organ protection offered by the trial drugs.
Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor. [1997.09]
The concept of initiating treatment of mild-to-moderate hypertension with a low-dose combination of reserpine and the thiazide clopamide in comparison to monotherapy with an ACE inhibitor was investigated. A total of 127 adult outpatients with diastolic blood pressure between 100 and 114 mmHg were randomized into this double-blind, parallel group study...
Different concepts in first-line treatment of essential hypertension. Comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy. German Reserpine in Hypertension Study Group. [1997.02]
Low-dose combination therapy has been proposed as a rational first-line approach to hypertension treatment. We compared the efficacy and tolerability of the fixed combination of reserpine (0.1 mg) plus the thiazide clopamid (5 mg) with its single components and the calcium-antagonist nitrendipine (20 mg) in a randomized, double-blind, parallel study of 273 hypertensive patients with diastolic blood pressure (BP) between 100 and 114 mm Hg...
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). [1995.12]
The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension. Participants were randomized to either chlorthalidone (2371), with step-up to atenolol, or reserpine if needed, or placebo (2365)...
Clinical Trials Related to Reserpine
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension [Recruiting]
This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for
three months among patients with pulmonary arterial hypertension.
Reserpine for the Treatment of Cocaine Dependence - 1 [Active, not recruiting]
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1 [Active, not recruiting]
In this parallel group clinical pharmacology laboratory experiment, we will assess
pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous
methamphetamine dose and single oral doses of reserpine (0. 5 and 1. 0 mg) or placebo.
Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) [Completed]
The SHEP Pilot Study had six objectives, each designed to develop and test critical
components of a full scale trial directed at the health consequences of treating isolated
systolic hypertension (ISH) in the elderly.
l. To estimate and compare the yield of participants for randomization into a clinical trial
from various community groups using various recruitment techniques.
2. To estimate compliance with the visit schedule and to the prescribed double-blind
3. To estimate and compare the effectiveness of specified antihypertensive medications in
reducing the blood pressure.
4. To estimate and compare the unwanted effects of specified antihypertensive medication in
an elderly population.
5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this
6. To develop and test methods of ascertaining stroke and other disease endpoints.
Systolic Hypertension in the Elderly Program (SHEP) [Completed]
The primary objective was to assess whether long-term administration of antihypertensive
therapy to elderly subjects with isolated systolic hypertension reduced the combined
incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the
effect of long-term antihypertensive therapy on mortality from any cause in elderly people
with isolated systolic hypertension; possible adverse effects of chronic use of
antihypertensive drug treatment in this population; the effect of therapy on indices of
quality-of-life; the natural history of isolated systolic hypertension in the placebo